Systemic hypertension augments, whereas insulin-dependent diabetes down-regulates, endothelin A receptor expression in the mammary artery in coronary artery disease patients by Zygalaki, Eleni et al.
ORIGINAL ARTICLE
Cardiology Journal
2009, Vol. 16, No. 4, pp. 348–354
Copyright © 2009 Via Medica
ISSN 1897–5593
348 www.cardiologyjournal.org
Address for correspondence: Zenon S. Kyriakides, MD, PhD, FESC, Director, B Cardiology Department, Red Cross Hospital,
1 Erythrou Stavrou str., Athens 115 26, Greece, tel: (+30) 210 6414 705, 6414 587, 81 04 554, fax: (+30) 210-6414587,
e-mail: zskyr@otenet.gr
Received: 1.03.2009 Accepted: 10.04.2009
Systemic hypertension augments, whereas
insulin-dependent diabetes down-regulates,
endothelin A receptor expression in the
mammary artery in coronary artery disease patients
Eleni Zygalaki1, Loukas Kaklamanis2, Maria Lolaka3, Nikolaos Nikolaou3,
Michael Koutouzis4, Evi S. Lianidou1, Zenon S. Kyriakides3
1Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Greece
2Onassis Cardiac Surgery Center, Athens, Greece
3Red Cross Hospital, Athens, Greece
4Sahlgrenska University Hospital, Gothenburg, Sweden
Abstract
Background: Endothelin (ET) A receptor antagonism causes decreased vasodilation in hy-
pertensive coronary arteries and decreased effects on coronary artery compliance in diabetic
patients.
Methods: We investigate the mRNA expression of ET-1, ETA and ETB receptors, using real
time RT-PCR, in biopsies from the internal mammary artery obtained from 49 patients,
18 diabetics and 34 hypertensives, all undergoing coronary artery bypass grafting.
Results: Hypertensive patients had higher ET-1 mRNA expression (16438 [8417, 23917]),
than normotensive patients (2974 [2283, 18055], p=0.008). Diabetic patients had signifi-
cantly lower ETA receptor levels than non-diabetic patients (455 [167, 1496] vs. 1660 [700,
3190], respectively, p = 0.003).
Conclusions: Multivariate analysis demonstrated that the presence of systemic hypertension
was the only independent predictor of log ETA receptor expression and log ET-1 expression,
while insulin-dependent diabetes was negatively correlated with ETA receptor expression. ETB
receptor expression was not correlated with any predictor. Systemic hypertension is associated
with increased ET-1 and ETA receptor mRNA expression, whereas insulin-dependent diabetes
down-regulates ETA receptor mRNA expression in the internal mammary artery in patients
with coronary artery disease undergoing bypass grafting. (Cardiol J 2009; 16, 4: 348–354)
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Introduction
Endogenous production of endothelin-1 (ET-1)
contributes to the maintenance of coronary vascu-
lar tone in coronary artery disease and healthy con-
trols [1]. In animal models of diabetes, reduced re-
sponsiveness to ET-1 is seen in both the large ves-
sels and the microvasculature [2, 3]. In addition,
both exogenous and endogenous ET-1 cause im-
paired vasoconstriction in forearm arteries of
patients with type 2 diabetes mellitus [4, 5]. Great-
er compensatory vessel enlargement occurs in
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patients with unstable than in those with stable cor-
onary syndromes, and is associated with increased
coronary artery distensibility [6, 7]. In diabetic pa-
tients, coronary compliance is decreased [8]. Re-
cently, we showed that ETA receptor antagonists
improve coronary artery compliance in patients with
atherosclerotic vessels [9].
ET-1 binds to at least two receptors. The ETA
receptor appears to be the major receptor causing
vasoconstriction in arteries; the ETB receptor me-
diates release of endothelium-dependent vasodila-
tor substances and is also present in some resist-
ance and capacitance arteries, where it contributes
to vasoconstriction [10]. ET-1 may play a part in the
pathophysiology of several conditions associated
with vasoconstriction, including chronic heart fail-
ure, essential hypertension, Reynaud’s disease, and
renal failure [10]. Furthermore, ET-1 influences salt
and water homeostasis, increases central and pe-
ripheral sympathetic activity and stimulates the
generation of renin, angiotensin II, aldosterone and
adrenaline [11]. It has been shown recently that the
effect of endogenous ET-1 on coronary artery stiff-
ness is impaired in type 2 diabetes mellitus [12],
and that ETA antagonism causes decreased vasodila-
tion, but does not have any differential effect on coro-
nary artery compliance in hypertensive patients [13].
We also know that vascular smooth muscle and
most other vascular tissues are less sensitive to the
effects of ET in hypertensive animals [14].
We hypothesized that the mRNA expression of
ET-1 and its receptors would be altered in patients
with diabetes mellitus and systemic hypertension.
The aim of the present study was to examine the
mRNA expression of ET-1 and its receptors in the
internal mammary artery in patients with coronary
artery disease, with and without diabetes and sys-
temic hypertension, undergoing coronary artery
bypass grafting.
Methods
Selection of patients
Forty-nine consecutive patients, 18 of whom
were type 2 diabetics (five having insulin-dependent
diabetes), and 34 hypertensives undergoing coro-
nary artery bypass graft for stable angina pectoris
class II or more, were enrolled in the study.
Ten of the patients had both type 2 diabetes
and hypertension. The patients’ characteristics are
presented in Table 1. Diabetes was defined as fast-
ing plasma glucose ≥ 126 mg/dL or two hours post
load plasma glucose ≥ 200 mg/dL or use of antidia-
betic medications in order to maintain normal plasma
glucose values. However, all patients with diabetes
in our study were under antidiabetic medication
treatment in order to control their glucose levels
(only antidiabetic tablets [n = 13] and/or insulin
[n = 5]). Hypertension was defined as systolic blood
pressure more than 140 mm Hg or diastolic blood
pressure more than 90 mm Hg or use of medica-
tion in order to maintain normal blood pressure
values. Patients were excluded from the study in
the presence of: acute myocardial infarction, unsta-
ble angina, heart failure, left ventricular ejection
fraction < 45% (estimated by left ventricular angio-
graphy), systolic pulmonary artery pressure
> 50 mm Hg (estimated by echocardiographic stud-
ies), plasma creatinine > 1.8 mg/dL, atrial fibrilla-
tion, additional cardiac disease or severe non-car-
diac disease. Medical histories were collected from
patients and their relatives and from medical files
as well as from laboratory examinations performed
in our institution. During the operation, a tiny part
of the distal end of the left internal mammary ar-
tery was obtained from all patients, immediately
frozen in liquid nitrogen and stored at –80°C until
analyzed.
The Hospital Ethics Committee approved the
study. All patients gave written informed consent.
RNA extraction and cDNA synthesis
Total cellular RNA was isolated using the Qia-
gen RNeasy Mini Reagent Set (Qiagen, Germany)
Table 1. Characteristics of the 49 patients studied.
Age 66 (59–73)
Male sex 42 (86%)
DM 18 (37%)
Non insulin-dependent DM 13 (27%)
Statin use 29 (59%)
Systemic hypertension 34 (69%)
History of myocardial infarction 23 (47%)
Beta-blocker use 12 (24%)
Nitrate use 39 (80%)
Calcium channel blocker use 14 (29%)
Diuretic use 8 (16%)
ACEI or AT-1 use 32 (65%)
Cholesterol [mg%] 202 (193–219)
Triglycerides [mg%] 155 (144–185)
LDL-cholesterol [mg%] 106 (63–124)
HDL-cholesterol [mg%] 38 (35–41)
LVEF (%) 55 (45–60)
Glycosylated hemoglobin 5.9 (5.5–6.8)
DM — diabetes mellitus; ACE — angiotensin converting enzyme
inhibitor; AT1 — angiotensin 1 receptor blocker; LVEF — left ventricular
ejection fraction
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according to the manufacturer’s recommendations.
All preparation and handling steps of RNA took
place in a laminar flow hood, under RNAse free con-
ditions. The concentration and purity of the RNA
were determined by spectrophotometric analysis at
260 and 280 nm and the isolated RNA was stored at
–80°C until further manipulations. Reverse transcrip-
tion of RNA was carried out with the SuperScript III
Platinum Two-Step qRT-PCR kit (Invitrogen, Cali-
fornia, USA) according to the manufacturer’s instruc-
tions, using 1 µg of total RNA as template.
Real time PCR
For the quantification of each gene of interest,
a real time PCR assay was developed. The primers
and probes were designed using the Primer Pre-
mier software. The oligonucleotides designed were
intron spanning in order to prevent amplification of
genomic DNA; their sequences are presented in
Table 2. For ET-1 the primers hybridize to exons
1/2 (F) and 2/3 (R) and therefore the mRNA that cor-
responds to the active peptide ET-1 is quantified.
Real time PCR was performed in the LightCy-
cler Instrument (Roche Applied Science, Germany)
in a total volume of 10 mL per glass capillary. For
each reaction 1 mL of cDNA was placed in a 9 mL
reaction mix containing 0.1 mL of a temperature-
released Taq DNA polymerase (5 U/mL; Platinum
DNA Polymerase; Invitrogen), 1 mL of the supplied
10 × PCR buffer, 0.7 mL (for ET-1) or 1.0 mL (for
ETAR and ETBR) of the supplied MgCl2 (50 mM),
0.2 mL of deoxynucleotide triphosphates (10 mM;
Invitrogen), 0.15 µL of bovine serum albumin
(10 mg/mL; Sigma), 0.5 mL of the primers (3 mM),
1 mL of the probe (3 mM), and diethylpyrocarbonate-
-treated H2O. The cycling protocol was identical for
the ET-1 and ETB receptors and consisted of an in-
itial five minute denaturation step at 95°C for acti-
vation of the DNA polymerase, followed by 45 cy-
cles of denaturation at 95°C for ten seconds, anneal-
ing at 60°C for 15 seconds, and extension at 72°C
for 15 seconds. The cycling protocol for the ETA
receptor consisted of an initial five minute denatur-
ation step at 95°C for activation of the DNA poly-
merase, followed by 45 cycles of denaturation at
95°C for ten seconds, annealing at 60°C for 15 se-
conds, and extension at 65°C for 20 seconds. For the
normalization of our results, the glyceraldehyde-3-
-phosphate dehydrogenase (GAPDH) gene was used
and the quantification was performed as previously
described [15].
To establish a specific, sensitive, and reproduc-
ible real time PCR assay, we performed extensive
optimization of primers, probes, and MgCl2 concen-
trations, as well as reaction temperatures and times.
The analytical evaluation of the assay and the quan-
tification of the genes’ expression levels were per-
formed with calibrators prepared and quantified as
previously described [14]. For each gene, a calibra-
tion curve was generated from serial dilutions rang-
ing from 106 to 102 copies/mL of the target of inter-
est. All calibration curves showed linearity over the
entire quantification range with correlation coeffi-
cients > 0.99.
Statistical analysis
Data for each continuous variable was exami-
ned with the Shapiro-Wilk’s W test to determine
whether assumptions of normality were valid. Con-
tinuous variables are summarized as median (25th,
75th centiles) unless stated otherwise. Since the data
was non-normally distributed, non-parametric tests
were used. Comparisons between continuous varia-
bles were done using the Mann-Whitney U test.
Unadjusted associations between the genes inves-
tigated and independent variables were tested us-
ing Spearman’s rank R. Adjusted associations were
tested using multiple linear regression analysis with
Table 2. Sequence of primers and probes used in this study.
Oligonucleotide Sequence (5’-3’) Base pair
ET-1 forward primer CCAGAAACAGCAGTCTTAGGCG 22
ET-1 reverse primer AACGTGCTCGGGAGTGTTGA 20
ET-1 probe 6FAM-CTCCTGCTCGTCCCTGATGGATAAAGAGTGTG-TMR 32
ETA receptor forward primer AACATCTTAAGCAGCGTCGAGAA 23
ETA receptor reverse primer GCAGAGGCATGACTGGAAACAAT 23
ETA receptor probe 6FAM-ATTTTTGCTCTTTGCTGGTTCCCTGTTCATTTA-TMR 33
ETB receptor forward primer ACCTAAAGCAGAGACGGGAAGTG 23
ETB receptor reverse primer CCAATACCAACAGAAAGCTCAAAAG 25
ETB receptor probe 6FAM-AACCGTCTTTTGCCTGGTCCTTGTCTTTGC-TMR 30
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log ET-1 expression, log ETA receptor and log ETB
receptor as independent variables. Variables that
reached levels of significance £ 0.20 during uni-
variate analysis were included in the multivariate
analysis. Descriptive data for continuous variables
are summarized as median (25th, 75th centiles) un-
less stated otherwise. For hypothesis testing, two-
-sided p values below 0.05 were considered to be
statistically significant. Data was analyzed with the
Statistica software (version 7.0, StatSoft Inc, USA).
Results
Endothelin-1 mRNA expression
Diabetic patients tended to have lower ET-1
mRNA expression than non-diabetic patients (8235
[4707, 15635] vs. 18055 [5724, 31621], p = 0.09).
Hypertensive patients had higher ET-1 mRNA ex-
pression (16438 [8417, 23917]) than normotensive
patients (2974 [2283, 18055], p = 0.008) (Fig. 1).
The results of the univariate analysis are
shown in Table 3. Six variables were associated with
ET-1 expression with a p value < 0.20 and were
entered into the multivariate analysis. The pres-
ence of arterial hypertension was the only inde-
pendent predictor of log ET-1 expression levels.
After adjustment for other variables, the presence
of arterial hypertension accounted for a mean in-
crease of 0.88 in log ET-1 expression.
Endothelin A receptor mRNA expression
Diabetic patients had significantly lower ETA
receptor levels than non-diabetic patients (455 [167,
Figure 1. Endothelin-1 mRNA expression in non-hyper-
tensive (n = 15) and hypertensive (n = 34) patients.
Table 3. Univariate and multivariate predictors for endothelin 1 (ET1) expression.
Univariate predictors Spearman R t p
Age 0.07 0.47 0.64
Female sex 0.18 1.24 0.22
Diabetes mellitus 0.25 1.76 0.09
Non insulin-dependent diabetes mellitus –0.20 –1.37 0.18
Insulin-dependent diabetes mellitus –0.11 –0.76 0.45
Glycosylated hemoglobin –0.16 –0.64 0.52
Cholesterol 0.21 1.49 0.14
High density lipoprotein-cholesterol –0.30 –2.17 0.04
Statin use –0.22 –1.55 0.13
Systemic hypertension 0.38 2.83 0.008
Left ventricular ejection fraction 0.13 0.92 0.36
Old myocardial infarction –0.08 –0.54 0.59
Beta-blocker use 0.14 1.00 0.32
Clopidogrel use –0.02 –0.12 0.91
Nitrate use 0.06 0.42 0.68
Calcium channel blocker use 0.01 0.04 0.97
ACEI or angiotensin 1 receptor blocker use 0.07 0.48 0.63
Multivariate predictors for Log ET-1 expression Beta SE beta p
Diabetes mellitus 0.30 0.53 0.58
Non insulin-dependent diabetes –0.23 0.56 0.90
Cholesterol 0.01 0.01 0.20
High density lipoprotein-cholesterol –0.02 0.03 0.49
Statin use 0.03 0.36 0.94
Systemic hypertension 0.98 0.38 0.01
ACEI — angiotensin converting enzyme inhibitor
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pendent diabetes down-regulates ETA receptor
mRNA expression in the internal mammary artery
in patients with coronary artery disease undergo-
ing bypass grafting.
1496] vs. 1660 [700, 3190], p = 0.003). Patients with
insulin-dependent diabetes mellitus had lower va-
lues than non-diabetic patients, whereas the differ-
ence between non-diabetic patients and those with
non insulin-dependent diabetes was of borderline
significance (Fig. 2). Univariate predictors for ETA
receptor levels are shown in Table 4. After adjust-
ment for other variables, both systemic hyperten-
sion and insulin-dependent diabetes were independ-
ent predictors for log ETA receptor levels. Log ETA
receptor levels were associated with ET-1 expres-
sion (R = 0.39, p = 0.008) (Fig. 3).
Endothelin B receptor mRNA expression
Univariate and multivariate predictors for ETB
receptors are shown in Table 5. In multivariate anal-
ysis there was only a borderline association be-
tween the presence of systemic hypertension and
ETB receptors.
Discussion
Our study demonstrates, for the first time, that
systemic hypertension increases ET-1 and ETA
receptor mRNA expression, whereas insulin-de-
Figure 2. Endothelin A (ETA) receptor mRNA expression
in non-diabetics (NDM) (n = 31), insulin-dependent dia-
betics (IDDM) (n = 5) and non insulin-dependent dia-
betics (NIDDM) (n = 13).
Table 4. Univariate and multivariate predictors for endothelin-1 (ET-1) receptors.
Univariate predictors Spearman R t p
Age 0.04 0.25 0.80
Female sex 0.08 0.50 0.62
Diabetes mellitus 0.45 3.31 0.002
Non insulin-dependent diabetes –0.25 –1.68 0.10
Insulin-dependent diabetes –0.34 –2.43 0.02
Glycosylated hemoglobin –0.12 –0.70 0.49
Cholesterol 0.18 1.22 0.23
High density lipoprotein-cholesterol –0.23 –1.55 0.12
Statin use –0.10 –0.68 0.50
Systemic hypertension 0.35 2.44 0.02
Left ventricular ejection fraction –0.12 –0.79 0.43
Old myocardial infarction 0.00 0.03 0.97
Beta-blocker use –0.04 –0.25 0.81
Clopidogrel use –0.07 –0.48 0.64
Nitrate use 0.03 0.21 0.84
Calcium channel blocker use 0.00 0.01 0.99
ACEI or angiotensin 1 receptor blocker use –0.10 –0.69 0.50
Multivariate predictors Beta SE beta p
Non insulin-dependent diabetes –1.0 0.67 0.14
Insulin-dependent diabetes –2.8 0.8 0.0006
Glycosylated hemoglobin 0.1 0.27 0.71
High density lipoprotein-cholesterol 0.02 0.04 0.54
Systemic hypertension 1.06 0.43 0.03
ACEI — angiotensin converting enzyme inhibitor
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To our knowledge, no studies have examined
the mRNA expression of ET-1 and its receptors in
the diabetic and hypertensive human internal mam-
mary arteries in coronary artery disease patients.
We chose to study the internal mammary ar-
tery because this special artery is resistant to
atherosclerosis [16].
It has been demonstrated that ET-1 exerts
a tonic stiffening effect on the in vitro common ca-
rotid artery and that this effect is mediated via the
ETA receptor [17].  In animal models of diabetes and
in patients with type 2 diabetes mellitus, a reduced
responsiveness to ET-1 is seen in both the large
peripheral vessels and the microvasculature [2–5].
Recently, a human study demonstrated that the ef-
fect of endogenous ET-1 on ETA receptors in the
periphery is enhanced in the resistance vessels of
patients with diabetes, whereas their sensitivity to
exogenous ET-1 is blunted [18]. These discrepan-
cies between the results of the different studies
could be ascribed to the following:
— the patient’s quality of glucose control. It is pos-
sible that a worse metabolic milieu may have
affected the vasodilatory mechanisms seconda-
ry to ETA receptor blockade;
— the medications the patients were taking, and
whether those medications had been stopped
before the study. Also, the average duration of
diabetes in the population may have contribu-
ted to the difference between the groups’ res-
ponses;
Figure 3. Relation between log endothelin-1 (ET-1) and
log endothelin A (ETA) receptor mRNA expression.
Table 5. Univariate and multivariate predictors for endothelin B receptors.
Univariate predictors Spearman t p
Age 0.06 0.39 0.70
Female sex –0.10 –0.65 0.52
Diabetes mellitus 0.22 1.54 0.13
Non insulin-dependent diabetes –0.07 –0.50 0.62
Insulin-dependent diabetes –0.24 –1.70 0.10
Glycosylated hemoglobin –0.16 –1.15 0.26
Cholesterol 0.01 0.08 0.94
Triglycerides 0.14 0.95 0.35
High density lipoprotein-cholesterol –0.24 –1.70 0.10
Statin use –0.18 –1.22 0.23
Systemic hypertension 0.33 2.34 0.02
Left ventricular ejection fraction –0.07 –0.46 0.65
Old myocardial infarction –0.08 –0.58 0.57
Blood glucose levels –0.18 –1.26 0.21
Beta-blocker use 0.07 0.47 0.64
Clopidogrel use 0.00 0.00 1.00
Nitrate use 0.00 0.03 0.98
Calcium channel blocker use 0.11 0.72 0.47
ACEI or angiotensin 1  receptor blocker use 0.11 0.78 0.44
Multivariate predictors Beta SE beta p
Diabetes mellitus 0.41 0.39 0.29
Insulin-dependent diabetes –0.40 0.62 0.52
High density lipoprotein-cholesterol –0.01 0.03 0.68
Systemic hypertension 0.68 0.39 0.09
ACEI — angiotensin converting enzyme inhibitor
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— inter-individual variability, or other unrecogni-
zed factors;
— gender issues;
— small study sample.
The down-regulation of the ETA receptor
mRNA expression we found in diabetics could ex-
plain the reduced responsiveness to ET-1 that is
demonstrated in large vessels and the impaired
response to ETA receptor antagonists as regards
coronary artery compliance in diabetic patients. This
is in accordance with a previous study of ours [12].
The present study, showing that systemic hyper-
tension increases ET-1 and ETA receptor mRNA ex-
pression in the left internal artery in patients undergo-
ing coronary artery bypass grafting, could explain our
previous findings showing that ETA antagonism caus-
es decreased vasodilation in coronary arteries [13] and
that the epicardial coronary vasculature in hyperten-
sive patients is less responsive to baseline ET during
coronary angioplasty [19]. Schneider et al. demonstrat-
ed that plasma ET is increased in early essential hy-
pertension [20]. The higher ET-1 and ETA receptor
mRNA expression found in the arteries of hyperten-
sive patients might result in a condition where higher
levels of ETA receptor blockers are needed in order to
reverse these patients’ increased vasomotor tone.
Conclusions
Systemic hypertension is associated with in-
creased ET-1 and ETA receptor mRNA expression,
while insulin-dependent diabetes down-regulates
ETA receptor mRNA expression in the internal mam-
mary artery in patients with coronary artery disease
undergoing bypass grafting. This could help explain
the differential response of hypertensive and diabetic
animals and humans to external and internal stimu-
lation and blockade of ET-1 and its receptors.
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